Hydroxychloroquine may not increase the risk of cardiotoxicity in RA patients, according to findings presented during ACR Convergence 2020.
FDA Provides 2020 Rheumatology Drug Update
Three FDA representatives discuss new drug indications, safety precautions and label changes, & an emergency program to rapidly evaluate existing immunomodulating therapies for use in COVID-19 patients.
A Closer Look at Antibodies in RA: How Anti-Citrullinated Protein Antibodies, Anti-Modified Protein Autoantibodies & Rheumatoid Factor Activity Overlap
Recent evidence on how anti-citrullinated protein antibodies, anti-modified protein autoantibodies and rheumatoid factor activity overlap in RA demonstrate new ideas for diagnostics and pathophysiology.
Therapeutic Exercise for Bone Health
ACR CONVERGENCE 2020—Attention to bone health in people at risk of developing, or who already have, osteoporosis is essential to reduce their increased risk for fragility fractures. Major risk factors for osteoporosis include being female, white, of small frame and having a family history of osteoporosis, as well as having secondary causes of osteoporosis, such…
Back to Basics: The 2020 Basic Science Year in Review
The 2020 Basic Science Year in Review covered autoantibody origin and persistence, insights into the major histocompatibility complex and factors in rheumatoid arthritis progression and relapse.
Telerheumatology: What’s Next?
In an ACR Convergence session, two rheumatologists discussed how COVID-19 changed the use of telemedicine, how payers reacted and which changes are likely permanent and which are likely to be temporary.
Evaluation & Treatment of Systemic Sclerosis-ILD in the New Decade
ACR Convergence panelists discussed how to monitor SSc-ILD patients for ILD severity & the brightening prospects for therapy.
The 2020 ACR Review Course: Key Issues Rheumatologists Face
The ACR Review Course featured eight talks providing a practical review of issues encountered by rheumatologists.
New Clinical Insights into the Pathogenesis, Diagnosis & Treatment of Calcium Pyrophosphate Arthritis
New diagnostic approaches combined with new evidence about pathogenesis are providing opportunities to help rheumatologists manage calcium pyrophosphate deposition disease.
Long-Term Safety of Baricitinib for RA
Baricitinib appears to be a safe long-term treatment for RA patients, according to a recent analysis of patients with drug exposure up to eight years.
- « Previous Page
- 1
- …
- 27
- 28
- 29
- 30
- 31
- …
- 36
- Next Page »